


## **APPENDIX 16B: CLINICAL EVIDENCE FOREST PLOTS: PHARMACOLOGICAL INTERVENTIONS**

Low-dose fluphenazine versus ultra low-dose fluphenazine.....	2
Antidepressants versus placebo.....	2
Flupenthixol versus placebo.....	2
Lithium versus placebo.....	3
Omega-3 fatty acid supplement versus placebo. ....	5


1 Low-dose fluphenazine versus ultra low-dose fluphenazine

1.1 Repetition during 6 months after trial entry




2 Antidepressants versus placebo

2.1 Per protocol repetition during first 6 months




2.2 Per protocol repetition at last follow-up




3 Flupenthixol versus placebo

3.1 Repetition during 6 months after trial entry




### 3.2 Compliance




### 4 Lithium versus placebo


#### 4.1 Repetition at 12 months from trial entry




#### 4.2 Depression (HDRS)



4.3 Hopelessness (BHS)




4.4 Depression (HAM-D)




5 Omega-3 fatty acid supplement versus placebo


5.1 Repetition during 12-week treatment phase



5.2 Depression after 6 months



5.3 Adherence



5.4 Reported suicide ideation at 12 weeks after trial entry

